Name: Recombinant Plasma Protein Therapeutics Market Outlook, Share, Competitive Landscape and Market Forecast 2023-2030
Brand: DataM Intelligence
SKU: DMPH1275
Price: 4350 USD
Availability: InStock

Recombinant Plasma Protein Therapeutics Market Outlook, Share, Competitive Landscape and Market Forecast 2023-2030 | DataM Intelligence

Recombinant Plasma Protein Therapeutics Market Outlook, Share, Competitive Landscape and Market Forecast 2023-2030

<h2>Global Recombinant Plasma Protein Therapeutics Market is segmented&nbsp;By Disease Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others),&nbsp;By Drug Type (Recombinant Coagulation Factors&nbsp;(Recombinant Coagulation Factor VIII, Recombinant Coagulation Factor IX), Human C1 Esterase Inhibitor),&nbsp;By Cell Line (Chinese Hamster Ovary (CHO) Cell Line, Baby Hamster Kidney (BHK) Cell Line, Human Embryonic Kidney (HEK) Cell Line, Others),&nbsp;and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis,&nbsp;2023-2030</h2>

&nbsp;

<h2>Recombinant Plasma Protein Therapeutics Market Overview</h2>

<blockquote>
The Recombinant Plasma Protein Therapeutics Market&nbsp;is expected to grow at a high&nbsp;<a href="https://www.datamintelligence.com/download-sample/recombinant-plasma-protein-therapeutics-market">CAGR</a>&nbsp;during the forecasting period (2023-2030).
</blockquote>

Recombinant Plasma Protein Therapeutics Market Summary and Scope

<table border="1" cellpadding="1" cellspacing="1">
	<tbody>
		<tr>
			<td>
			Metrics
			</td>
			<td>
			Details
			</td>
		</tr>
		<tr>
			<td>
			Market&nbsp;CAGR
			</td>
			<td>
			High
			</td>
		</tr>
		<tr>
			<td>
			Segments Covered
			</td>
			<td>
			By Disease Type,&nbsp;By Drug Type,&nbsp;By Cell Line,&nbsp;and By Region
			</td>
		</tr>
		<tr>
			<td>
			Report Insights Covered
			</td>
			<td>
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
			</td>
		</tr>
		<tr>
			<td>
			Fastest Growing Region
			</td>
			<td>
			Asia Pacific
			</td>
		</tr>
		<tr>
			<td>
			Largest Market Share&nbsp;
			</td>
			<td>
			North America
			</td>
		</tr>
	</tbody>
</table>

&nbsp;

To Get a Free Sample&nbsp;<a href="https://www.datamintelligence.com/download-sample/pet-radiotracer-market">Click here</a>

&nbsp;

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Trending Topics</h2>

<a href="https://www.datamintelligence.com/research-report/plasma-protein-therapeutics-market">Plasma Protein Therapeutics Market</a>

<a href="https://www.datamintelligence.com/research-report/plasma-protease-c1-inhibitor-treatment-market">Plasma Protease C1-Inhibitor Treatment Market</a>

<a href="https://www.datamintelligence.com/research-report/poems-syndrome-market">POEMS Syndrome Market</a>

<h3>&nbsp;</h3>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Contents</h2>

1. Methodology and Scope

1.1. Research Methodology

1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1.&nbsp;Market Snippet by Disease Type

3.2. Market Snippet by Drug Type

3.3. Market Snippet by Cell Line

3.4. Market Snippet by Region

3.5. DataM CLO Scenario

4. Dynamics

4.1. Market Impacting Factors

4.1.1. Drivers

4.1.1.1. Increase in new product launches

4.1.1.2. Rise in awareness about rare disease treatment

4.1.1.3. Increase in investment

4.1.1.4. Rising prevalence of hematological disease

4.1.2. Restraints

4.1.2.1. High cost of treatment

4.1.2.2. Rise in alternative therapies

4.1.3. Opportunity

4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter&#39;s Five Forces Analysis

5.2. Regulatory Analysis

6. Epidemiology Analysis

7. Pipeline Analysis

8. By Disease Type

8.1. Introduction

8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

8.3. Market Attractiveness Index, By Disease Type

8.4. Hemophilia A

8.4.1. Introduction

8.4.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026

8.5.&nbsp;Hemophilia B

8.6. Von Willebrand Disease

8.7.&nbsp;Others

9. By Drug Type

9.1. Introduction

9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

9.3. Market Attractiveness Index, By Drug Type

9.4.&nbsp;Recombinant Coagulation Factors

9.4.1. Introduction

9.4.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)

9.4.3. Recombinant Coagulation Factor VIII

9.4.4. Recombinant Coagulation Factor IX

9.5.&nbsp;Human C1 Esterase Inhibitor

10. By Cell Line

10.1. Introduction

10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cell Line

10.3. Market Attractiveness Index, By Cell Line

10.4. Chinese Hamster Ovary (CHO) Cell Line

10.4.1. Introduction

10.4.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026

10.5. Baby Hamster Kidney (BHK) Cell Line

10.6. Human Embryonic Kidney (HEK) Cell Line

10.7. Others

11. By Region

11.1. Introduction

11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

11.3. Market Attractiveness Index, By Region

11.4. North America

11.4.1. Introduction

11.4.2. Key Region-Specific Dynamics

11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cell Line

11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11.4.6.1. U.S.

11.4.6.2. Canada

11.4.6.3. Mexico

11.5. Europe

11.5.1. Introduction

11.5.2. Key Region-Specific Dynamics

11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cell Line

11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11.5.6.1. Germany

11.5.6.2. U.K.

11.5.6.3. France

11.5.6.4. Italy

11.5.6.5. Spain

11.5.6.6. Rest of Europe

11.6. South America

11.6.1. Introduction

11.6.2. Key Region-Specific Dynamics

11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cell Line

11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11.6.6.1. Brazil

11.6.6.2. Argentina

11.6.6.3. Rest of South America

11.7. Asia Pacific

11.7.1. Introduction

11.7.2. Key Region-Specific Dynamics

11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cell Line

11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11.7.6.1. China

11.7.6.2. India

11.7.6.3. Japan

11.7.6.4. Australia

11.7.6.5. Rest of Asia Pacific

11.8. Middle East and Africa

11.8.1. Introduction

11.8.2. Key Region-Specific Dynamics

11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type

11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cell Line

&nbsp;

12. Global Market Competitive Landscape

12.1. Competitive Scenario

12.2. Competitor Recombinant Plasma Protein Therapeutics Strategy Analysis

12.3. Comparative Product Portfolio Analysis

12.4. Market Positioning/Share Analysis

12.5. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. CSL Limited *

13.1.1.&nbsp;&nbsp;Company Overview

13.1.2. Product Portfolio and Description

13.1.3. Key Highlights

13.1.4. Financial Overview

13.2. Takeda Pharmaceutical Company Limited

13.3. Octapharma

13.4. Novo Nordisk A/S

13.5. Bayer AG

13.6. Sanofi

13.7. Aptevo Therapeutics

13.8. Pharma Group NV

13.9. Pfizer Inc.

13.10. Viropharma Biologics, Inc.

13.11. Grifols S.A.

13.12. Biotest AG

13.13. Baxter

13.14. Kedrion SPA

14. DataM Intelligence

14.1. Appendix

14.2. About Us and Services

14.3. Contact Us

&nbsp;

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables and Figures</h2>

<h3>List of Tables</h3>

Table 1

Global Recombinant Plasma Protein Therapeutics Market Value, By Disease Type, 2021,2025 &amp; 2029 ($ Million)

Table 2

Global Recombinant Plasma Protein Therapeutics Market Value, By Drug Type, 2021,2025 &amp; 2029 ($ Million)

Table 3

Global Recombinant Plasma Protein Therapeutics Market Value, By Cell Line, 2021,2025 &amp; 2029 ($ Million)

Table 4

Global Recombinant Plasma Protein Therapeutics Market Value, By Region, 2021,2025 &amp; 2029 ($ Million)

Table 5

Global Recombinant Plasma Protein Therapeutics Market Value, By Disease Type, 2021,2025 &amp; 2029 ($ Million)

Table 6

Global Recombinant Plasma Protein Therapeutics Market Value, By Disease Type, 2017-2029 ($ Million)

Table 7

Global Recombinant Plasma Protein Therapeutics Market Value, By Drug Type, 2021,2025 &amp; 2029 ($ Million)

Table 8

Global Recombinant Plasma Protein Therapeutics Market Value, By Drug Type, 2017-2029 ($ Million)

Table 9

Global Recombinant Plasma Protein Therapeutics Market Value, By Cell Line, 2021,2025 &amp; 2029 ($ Million)

Table 10

Global Recombinant Plasma Protein Therapeutics Market Value, By Cell Line, 2017-2029 ($ Million)

Table 11

Global Recombinant Plasma Protein Therapeutics Market Value, By Region, 2021,2025 &amp; 2029 ($ Million)

Table 12

Global Recombinant Plasma Protein Therapeutics Market Value, By Region, 2017-2029 ($ Million)

Table 13

North America Recombinant Plasma Protein Therapeutics Market Value, By Disease Type, 2017-2029 ($ Million)

Table 14

North America Recombinant Plasma Protein Therapeutics Market Value, By Drug Type, 2017-2029 ($ Million)

Table 15

North America Recombinant Plasma Protein Therapeutics Market Value, By Cell Line, 2017-2029 ($ Million)

Table 16

North America Recombinant Plasma Protein Therapeutics Market Value, By Country, 2017-2029 ($ Million)

Table 17

South America Recombinant Plasma Protein Therapeutics Market Value, By Disease Type, 2017-2029 ($ Million)

Table 18

South America Recombinant Plasma Protein Therapeutics Market Value, By Drug Type, 2017-2029 ($ Million)

Table 19

South America Recombinant Plasma Protein Therapeutics Market Value, By Cell Line, 2017-2029 ($ Million)

Table 20

South America Recombinant Plasma Protein Therapeutics Market Value, By Country, 2017-2029 ($ Million)

Table 21

Europe Recombinant Plasma Protein Therapeutics Market Value, By Disease Type, 2017-2029 ($ Million)

Table 22

Europe Recombinant Plasma Protein Therapeutics Market Value, By Drug Type, 2017-2029 ($ Million)

Table 23

Europe Recombinant Plasma Protein Therapeutics Market Value, By Cell Line, 2017-2029 ($ Million)

Table 24

Europe Recombinant Plasma Protein Therapeutics Market Value, By Country, 2017-2029 ($ Million)

Table 25

Asia-Pacific Recombinant Plasma Protein Therapeutics Market Value, By Disease Type, 2017-2029 ($ Million)

Table 26

Asia-Pacific Recombinant Plasma Protein Therapeutics Market Value, By Drug Type, 2017-2029 ($ Million)

Table 27

Asia-Pacific Recombinant Plasma Protein Therapeutics Market Value, By Cell Line, 2017-2029 ($ Million)

Table 28

Asia-Pacific Recombinant Plasma Protein Therapeutics Market Value, By Country, 2017-2029 ($ Million)

Table 29

Middle East &amp; Africa Recombinant Plasma Protein Therapeutics Market Value, By Disease Type, 2017-2029 ($ Million)

Table 30

Middle East &amp; Africa Recombinant Plasma Protein Therapeutics Market Value, By Drug Type, 2017-2029 ($ Million)

Table 31

Middle East &amp; Africa Recombinant Plasma Protein Therapeutics Market Value, By Cell Line, 2017-2029 ($ Million)

Table 32

CSL Limited: Overview

Table 33

CSL Limited: Product Portfolio

Table 34

CSL Limited: Key Developments

Table 35

Takeda Pharmaceutical Company Limited: Overview

Table 36

Takeda Pharmaceutical Company Limited: Product Portfolio

Table 37

Takeda Pharmaceutical Company Limited: Key Developments

Table 38

Octapharma: Overview

Table 39

Octapharma: Product Portfolio

Table 40

Octapharma: Key Developments

Table 41

Novo Nordisk A/S: Overview

Table 42

Novo Nordisk A/S: Product Portfolio

Table 43

Novo Nordisk A/S: Key Developments

Table 44

Bayer AG: Overview

Table 45

Bayer AG: Product Portfolio

Table 46

Bayer AG: Key Developments

Table 47

Sanofi: Overview

Table 48

Sanofi: Product Portfolio

Table 49

Sanofi: Key Developments

Table 50

Aptevo Therapeutics: Overview

Table 51

Aptevo Therapeutics: Product Portfolio

Table 52

Aptevo Therapeutics: Key Developments

Table 53

Pharma Group NV: Overview

Table 54

Pharma Group NV: Product Portfolio

Table 55

Pharma Group NV: Key Developments

Table 56

Pfizer Inc.: Overview

Table 57

Pfizer Inc.: Product Portfolio

Table 58

Pfizer Inc.: Key Developments

Table 59

Viropharma Biologics, Inc.: Overview

Table 60

Viropharma Biologics, Inc.: Product Portfolio

Table 61

Viropharma Biologics, Inc.: Key Developments

&nbsp;

<h3>List of Figures</h3>

Figure 1

Global Recombinant Plasma Protein Therapeutics Market Share, By Disease Type, 2021 &amp; 2029 (%)

Figure 2

Global Recombinant Plasma Protein Therapeutics Market Share, By Drug Type, 2021 &amp; 2029 (%)

Figure 3

Global Recombinant Plasma Protein Therapeutics Market Share, By Cell Line, 2021 &amp; 2029 (%)

Figure 4

Global Recombinant Plasma Protein Therapeutics Market Share, By Region, 2021 &amp; 2029 (%)

Figure 5

Global Recombinant Plasma Protein Therapeutics Market Value, 2017-2029 ($ Million)

Figure 6

Global Recombinant Plasma Protein Therapeutics Market Y-o-Y Growth, By Disease Type, 2021-2029 (%)

Figure 7

Hemophilia A: Global Recombinant Plasma Protein Therapeutics Market Value, 2017-2029 ($ Million)

Figure 8

Hemophilia B: Global Recombinant Plasma Protein Therapeutics Market Value, 2017-2029 ($ Million)

Figure 9

Von Willebrand Disease: Global Recombinant Plasma Protein Therapeutics Market Value, 2017-2029 ($ Million)

Figure 10

Others: Global Recombinant Plasma Protein Therapeutics Market Value, 2017-2029 ($ Million)

Figure 11

Global Recombinant Plasma Protein Therapeutics Market Y-o-Y Growth, By Drug Type, 2021-2029 (%)

Figure 12

Recombinant Coagulation Factors: Global Recombinant Plasma Protein Therapeutics Market Value, 2017-2029 ($ Million)

Figure 13

Human C1 Esterase Inhibitor: Global Recombinant Plasma Protein Therapeutics Market Value, 2017-2029 ($ Million)

Figure 14

Recombinant Coagulation Factor VIII: Global Recombinant Plasma Protein Therapeutics Market Value, 2017-2029 ($ Million)

Figure 15

Recombinant Coagulation Factor IX: Global Recombinant Plasma Protein Therapeutics Market Value, 2017-2029 ($ Million)

Figure 16

Global Recombinant Plasma Protein Therapeutics Market Y-o-Y Growth, By Cell Line, 2021-2029 (%)

Figure 17

Chinese Hamster Ovary (CHO) Cell Line: Global Recombinant Plasma Protein Therapeutics Market Value, 2017-2029 ($ Million)

Figure 18

Baby Hamster Kidney (BHK)&nbsp;Cell Line: Global Recombinant Plasma Protein Therapeutics Market Value, 2017-2029 ($ Million)

Figure 19

Human Embryonic Kidney (HEK) Cell Line: Global Recombinant Plasma Protein Therapeutics Market Value, 2017-2029 ($ Million)

Figure 20

Others: Global Recombinant Plasma Protein Therapeutics Market Value, 2017-2029 ($ Million)

Figure 21

Global Recombinant Plasma Protein Therapeutics Market Y-o-Y Growth, By Region, 2021-2029 (%)

Figure 22

North America Recombinant Plasma Protein Therapeutics Market Value, 2017-2029 ($ Million)

Figure 23

North America Recombinant Plasma Protein Therapeutics Market Share, By Disease Type, 2021 &amp; 2029 (%)

Figure 24

North America Recombinant Plasma Protein Therapeutics Market Share, By Drug Type, 2021 &amp; 2029 (%)

Figure 25

North America Recombinant Plasma Protein Therapeutics Market Share, By Cell Line, 2021 &amp; 2029 (%)

Figure 26

North America Recombinant Plasma Protein Therapeutics Market Share, By Country, 2021 &amp; 2029 (%)

Figure 27

South America Recombinant Plasma Protein Therapeutics Market Value, 2017-2029 ($ Million)

Figure 28

South America Recombinant Plasma Protein Therapeutics Market Share, By Disease Type, 2021 &amp; 2029 (%)

Figure 29

South America Recombinant Plasma Protein Therapeutics Market Share, By Drug Type, 2021 &amp; 2029 (%)

Figure 30

South America Recombinant Plasma Protein Therapeutics Market Share, By Cell Line, 2021 &amp; 2029 (%)

Figure 31

South America Recombinant Plasma Protein Therapeutics Market Share, By Country, 2021 &amp; 2029 (%)

Figure 32

Europe Recombinant Plasma Protein Therapeutics Market Value, 2017-2029 ($ Million)

Figure 33

Europe Recombinant Plasma Protein Therapeutics Market Share, By Disease Type, 2021 &amp; 2029 (%)

Figure 34

Europe Recombinant Plasma Protein Therapeutics Market Share, By Drug Type, 2021 &amp; 2029 (%)

Figure 35

Europe Recombinant Plasma Protein Therapeutics Market Share, By Cell Line, 2021 &amp; 2029 (%)

Figure 36

Europe Recombinant Plasma Protein Therapeutics Market Share, By Country, 2021 &amp; 2029 (%)

Figure 37

Asia-Pacific Recombinant Plasma Protein Therapeutics Market Value, 2017-2029 ($ Million)

Figure 38

Asia-Pacific Recombinant Plasma Protein Therapeutics Market Share, By Disease Type, 2021 &amp; 2029 (%)

Figure 39

Asia-Pacific Recombinant Plasma Protein Therapeutics Market Share, By Drug Type, 2021 &amp; 2029 (%)

Figure 40

Asia-Pacific Recombinant Plasma Protein Therapeutics Market Share, By Cell Line, 2021 &amp; 2029 (%)

Figure 41

Asia-Pacific Recombinant Plasma Protein Therapeutics Market Share, By Country, 2021 &amp; 2029 (%)

Figure 42

Middle East &amp; Africa Recombinant Plasma Protein Therapeutics Market Value, 2017-2029 ($ Million)

Figure 43

Middle East &amp; Africa Recombinant Plasma Protein Therapeutics Market Share, By Disease Type, 2021 &amp; 2029 (%)

Figure 44

Middle East &amp; Africa Recombinant Plasma Protein Therapeutics Market Share, By Drug Type, 2021 &amp; 2029 (%)

Figure 45

Middle East &amp; Africa Recombinant Plasma Protein Therapeutics Market Share, By Cell Line, 2021 &amp; 2029 (%)

Figure 46

CSL Limited: Financials

Figure 47

Takeda Pharmaceutical Company Limited: Financials

Figure 48

Octapharma: Financials

Figure 49

Novo Nordisk A/S: Financials

Figure 50

Bayer AG: Financials

Figure 51

Sanofi: Financials

Figure 52

Aptevo Therapeutics: Financials

Figure 53

Pharma Group NV: Financials

Figure 54

Pfizer Inc.: Financials

Figure 55

Viropharma Biologics, Inc.: Financials

&nbsp;

Metrics	Details
Market CAGR	High
Segments Covered	By Disease Type, By Drug Type, By Cell Line, and By Region
Report Insights Covered	Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.
Fastest Growing Region	Asia Pacific
Largest Market Share	North America